25 September, 2020

The regulatory approval and commercialisation of Luxturna in 2017 has opened the floodgates for gene therapy, with numerous clinical trials underway or rapidly approaching. Dr Tom Edwards and Dr Lauren Ayton will update Retina Australia members on the national approach to identifying and characterising people who might be eligible for these trials (through the Inherited Retinal Disease Natural History Study), as well as describing the most promising developments in the field.

This webinar will take place on Saturday 17th October at 2:00pm EST. You can find a copy of the flyer in Word version here or in PDF version here

Back to News

We can’t do what we do without you!

Other News

$1.5m NHMRC Partnership grant awarded to genetic blindness study

A $1.5m National Health and Medical Research Council (NHMRC) Partnership Grant has been awarded...

2024 Research Grants Announced

Retina Australia is delighted to announce two new Research Grant recipients for 2024. The new projects will focus on Stargardt disease and Virtual Reality...

Retina Australia’s website upgraded, rebranded and accessibility compliant

Retina's Australia's new website is now live, upgraded for...